Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 85,874 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Completed Not applicable Interventional

Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes

NCT00458133
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exercise
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
30 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 4 Interventional

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

NCT00792233
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Withdrawal of anti-TNF therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Nov 5, 2026, 5:03 AM EST
Terminated Not applicable Interventional

Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients

NCT04590833
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Supervised walking on a treadmill, Supervised stretching exercise
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Completed Not applicable Interventional Results available

Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT02002533
View directory record Official record
Conditions
Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention
Behavioral · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Decatur, Illinois • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Nov 5, 2026, 5:03 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Larotrectinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Engaging Partners in Caring Communities

NCT06932549
View directory record Official record
Conditions
Chronic Disease Prevention
Interventions
Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.
Behavioral
Lead sponsor
Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 1Phase 2 Interventional

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

NCT00836147
View directory record Official record
Conditions
Keloid
Interventions
Avotermin (Juvista), Placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Nov 5, 2026, 5:03 AM EST
Recruiting Not applicable Interventional

RELAXaHEAD for Headache Patients (Phase III)

NCT06077838
View directory record Official record
Conditions
Migraine
Interventions
RELAXaHEAD Smartphone App Version 1, RELAXaHEAD Smartphone App Version 2
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 1Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

NCT01514201
View directory record Official record
Conditions
Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Veliparib
Radiation · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 5, 2026, 5:03 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors

NCT02046265
View directory record Official record
Conditions
Cervical Cancer
Interventions
Step Up to Prevention, Step Up to Prevention: knowledge, Step Up to Prevention:belief, Offered HPV vaccine only
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 3 Interventional

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

NCT03073967
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, Investigator's choice
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
16 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
Deoxycholic Acid, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 5, 2026, 5:03 AM EST
Completed Not applicable Interventional Results available

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167
View directory record Official record
Conditions
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
Adaptive Bridging Radiation Therapy (ABRT)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Completed Not applicable Interventional Results available

A Novel Use of a Sleep Intervention to Target the Emotion Regulation Brain Network to Treat Depression and Anxiety

NCT04424407
View directory record Official record
Conditions
Insomnia, Depression
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 5, 2026, 5:03 AM EST
Recruiting Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

NCT07600736
View directory record Official record
Conditions
KCNT1-Related Epilepsy
Interventions
ABS-1230, Placebo
Drug
Lead sponsor
Actio Biosciences, Inc.
Industry
Eligibility
1 Month to 21 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hackensack, New Jersey • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transcranial Direct Current Stimulation (tDCS)-Enhanced Stroke Recovery

NCT01007136
View directory record Official record
Conditions
Ischemic Stroke
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Nov 5, 2026, 5:03 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

NCT05490771
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 5, 2026, 5:03 AM EST
Completed Phase 2 Interventional Results available

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

NCT00630344
View directory record Official record
Conditions
Prostate Cancer
Interventions
RAD001, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Nov 5, 2026, 5:03 AM EST
Withdrawn No phase listed Observational

Adjustable Gastric Band Survey Study

NCT01041534
View directory record Official record
Conditions
Morbid Obesity
Interventions
Survey
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Nov 5, 2026, 5:03 AM EST
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 5, 2026, 5:03 AM EST
Recruiting Not applicable Interventional

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

NCT07226934
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
GPT-QPL
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 5, 2026, 5:03 AM EST